Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in ...

Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

A new experimental weight loss drug from Amgen — the first in a growing group of drugs aimed at once-a-month injections instead of once a week — helped patients lose up to 20% of their weight in one ...

Goldman Sachs analyst Salveen Richter has maintained their bullish stance on AMGN stock, giving a Buy rating yesterday.Don't Miss our Black ...

MariTide has the advantage over rival treatments in that it ... which were mostly mild and associated with a first dose. The Phase 2 study showed people living with obesity or overweight and Type 2 ...

Amgen didn't clarify whether the average weight reduction of up to about 20% was a placebo-adjusted figure. It most likely referred to total weight loss, which means the candidate probably isn't any ...

Poseida Therapeutics Inc. is being bought out for $1.5 billion by partner Roche Holdings Inc. to allogeneic CAR T therapies to treat hematologic malignancies. The two companies began their ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

Amgen's phase 2 data disappointed, but its obesity pipeline still holds potential. See why AMGN stock is appealing even without the full upside from MariTide.